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ABSTRACT
A simple spectrophotometric method is described for the determination of acetylcysteine (I) and captopril (II) as representative
examples of thiols , as well as amlodipine besylate (III) and heptaminol hydrochloride (IV) as amine examples. The method is based
on the reaction of these drugs with the activated halide 2,4-dinitrofluorobenzene (DNFB) in aqueous borate buffer to yield yellow
colored products. Beer’s law was obeyed over the concentration ranges of 4-12, 2.4-16.8, 8-28 and 5-25 µg mL-1 for (I), (II), (III),
and (IV), respectively. The different experimental parameters were studied and optimized. The proposed method was validated
according to the USP 27 criteria and was found suitable for the quantitation of the cited compounds in their pharmaceutical preparations without interference from common excipients.
Key words: acetylcysteine, captopril, amlodipine besylate, heptaminol hydrochloride, spectrophotometry, dinitrofluorobenzene,
dosage forms

INTRODUCTION
Acetylcysteine, (N-acetyl-L-cysteine), is a mucolytic
agent used in respiratory disorders associated with active
cough(1). It has been determined in pharmaceutical preparations by several methods including spectrophotometry(2,3), spectrofluorimetry after reacting with different
derivatization agents (4,5), HPLC(6,7), capillary electrophoresis(8), and several voltammetric techniques (9,10).
Captopril, 1-[(2s)-3-mercapto-2-methylpropionyl]-Lproline, is a sulfhydryl-containing inhibitor of angiotensin
converting enzyme. It is used in the management of hypertension, heart failure following myocardial infarction, and
diabetic nephropathy(1). A full bibliography of captopril
up to 1982 is found in the analytical profile (11). The spectrophotometric methods used for the determination of this
drug are based on the reactivity of its tertiary nitrogen(12),
mercapto group(13,14) or complex formation(15,16). Captopril has also been assayed spectrofluorimetrically after
reacting with fluorogenic reagents(2) or reducing Ce (IV)
to fluorescent Ce (III)(17). Other techniques adopted for
the determination of captopril include voltammetry(18,19),
GC(20), HPLC(21,22), atomic absorption spectrophotometry(23), and capillary electrophoresis(24).
Amlodipine besylate, 3-ethyl-5-methyl-2(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl* Author for correspondence. Tel: +20-3-4868346;
Fax: +20-3-4873273; E-mail: haggag@tecmina.com

pyridine-3,5-dicarboxylate monobenzenesulphonate, is a
dihydropyridine calcium-channel blocker used in the
management of hypertension and angina pectoris (1).
Few spectrophotometric methods have been reported
for the determination of amlodipine besylate in its pharmaceutical dosage forms. These include: ion association complex formation with bromothymol blue (25) and
orange (II)(26), oxidative coupling with MBTH(25), charge
transfer complex formation with p-chloranilic acid (27)
and difference spectrophotometry from acidic to alkaline
solutions (28). The drug has also been determined in its
tablets by HPLC(29), HPTLC(30) and adsorptive squarewave anodic stripping voltammetry(31).
Heptaminol hydrochloride, 6-amino-2-methylheptan-2-ol hydrochloride, is a cardiac stimulant and vasodilator for the treatment of cardiovascular disorders (1).
Hantzch reaction followed by spectrophotometric and
spectrofluorimetric measurement of the absorbance and
fluorescence of the product has been a useful tool for the
determination of heptaminol in its pharmaceutical preparations (32). Other reported methods include HPLC after
pre-column derivatization and either UV(33,34) or electrochemical detection(35).
The purpose of the present work was to develop
a simple, rapid, accurate and sensitive method for the
determination of the selected drugs in their pharmaceutical preparations by reacting them with 2,4-dinitrofluorobenzene (DNFB) in borate buffer through nucleophilic
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aromatic substitution. The results obtained were found
to be in good agreement with reference methods.

MATERIALS AND METHODS

dry flasks. Aliquots of these solutions were then treated as
described above under the general procedure.
For drops: An aliquot of 0.1 mL of the drops was
diluted to 25 mL with methanol. The above stated general
procedure was applied to determine the drug concentration.

I. Apparatus
Measurements were performed using a PerkinElmer, lambda EZ 201 (Version 1.0) UV/VIS spectrophotometer equipped with 10 nm matched quartz cells and
connected to a Panasonic Quiet KX-P 3626 printer. The
spectral band width was 2.0 nm and the wavelength scanning speed was 200 nm/min. A Schott-Gerate pH meter
Model CG 710 calibrated with standard buffers was used
for adjusting the pH values of the buffer solution used.
II. Reagents and Materials
All of the chemicals and the reagents used were of
pure analytical grade.
Borate buffer was prepared as 0.05 M sodium tetraborate solution(36) and the pH was adjusted with 0.1M
sodium hydroxide or 0.1M boric acid.
2,4-Dinitrofluorobenzene reagent (Hopkin and
Williams Co., Essex-UK) was prepared as a 0.5% W/V
solution in methanol for compounds (I), (III) and (IV)
and as a 0.2% W/V solution for compound (II). These
solutions were freshly prepared and protected from light.
Stock solutions of compounds (I), (II), (III) and (IV)
were prepared as 0.2, 0.24, 0.4 and 0.5 mg mL -1 in methanol, respectively. The solution of compound (III) should
be protected from light.

RESULTS AND DISCUSSION
2,4-Dinitrofluorobenzene (DNFB) has been used in
pharmaceutical analysis for the determination of specific
functional groups such as primary and secondary amines,
phenols, thiols and imidazoles (37). In the present work
DNFB reacts through a nucleophilic aromatic substitution reaction with thiols as (I) and (II) and amines as
(III) and (IV) in aqueous alkaline medium to form yellow
colored products as proposed in equations (a-c).

RSH + F

NO2

O2 N

IV. Procedure for Dosage Forms
For tablets and sachets: Twenty tablets or five sachets
were weighed, powdered and mixed well. A portion equivalent to 20 mg of (I), 25 mg of (II), 40 mg of (III) or 50 mg
of (IV) was weighed and quantitatively transferred into
100-mL volumetric flasks using methanol. The flasks were
sonicated for 30 min and the volumes were completed to
the mark with methanol. The solutions were filtered into
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III. General Procedure
Aliquots from the stock solution of each drug (Table
1) were transferred into series of 10-mL volumetric flasks.
The specified volume of borate buffer of the optimum
pH was added to each flask, followed by the appropriate volume of DNFB solution (Table 1). The flasks were
heated on a water bath (the temperature and time of heating
are cited in Table 1) and then cooled to room temperature.
The volumes were made up to the mark with methanol and
the absorbances were measured at the corresponding λ max
(Table 1) against a reagent blank treated similarly after
neutralization of the solutions with 5 M hydrochloric acid.
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The reported applications of this reaction to determine
amine acid salts involved prior liberation of the base by
alkalinization and subsequent organic solvent extraction of
the basic drug. This step was omitted in the present study.
Heptaminol molecule contains a primary amino group
of sufficient basicity to attack the electron deficient polynitro aromatic compound DNFB, while amlodipine features
a primary aliphatic amino group and a dihydropyridine
nitrogen which is neutral and is therefore a poor candidate
for the reaction. The reaction stoichiometry between this
latter drug and the reagent has been ascertained by applying the mole ratio method. The results obtained indicate a
molar ratio of 1:1 thus confirming the participation of only
the primary amino group in the reaction (Figure 1). The
absorption spectra of the yellow colored products formed
at the optimum conditions show characteristic λ max as
reported in Table 1. The experimental conditions were
established by varying each parameter individually and
noting its effect on the absorbance of the products.
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Volume of 2,4 DNFB (mL)

Figure 1. Molar ratio plot for amlodipine besylate and 2,4-dimitroflu
orobenzene.

1

I. Matrix Effects

AC
CP
0.8

A [1cm]

The reaction was investigated over the pH range of 7.49.4 using borate buffer. The products showed the highest
absorptions in buffer of pH 7.8, 8, 7.8 and 8.5 for compounds
(I), (II), (III) and (IV), respectively (Figures 2 and 3).
To remove excess reagent interference in the absorbance measurement of the reaction products, this excess
was acid-hydrolyzed to colorless 2,4-dinitrophenol. The
volume of acid (5 M hydrochloric acid) necessary to
accomplish this task was determined (Table 1).
The optimum volumes of the buffer solutions were
found to be 0.5 mL for the two thiols and 0.4 mL for the
two amino compounds (Figures 4 and 5).
Effect of the reagent concentration on color development was also studied where it was found that 0.2 mL of
0.2% w/v reagent was sufficient to give the maximum color
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10
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Figure 2. Effect of buffer pH on the substit ution reaction of
acetylcysteine (11.14 μg mL -1) and captopril (14.01 μg mL -1) with
2,4-dinitrofluorobenzene.

Table 1. Assay parameters for the determination of acetylcysteine (I), captopril (II), amlodipine besylate (III) and heptaminol hydrochloride
(IV) by the proposed method
Drug
Item

I

II

III

IV

0.2

0.24

0.4

0.5

0.2-0.6

0.1-0.7

0.2-0.7

0.1-0.5

Borate buffer pH

7.8

8.0

7.8

8.5

Borate buffer volume (mL)

0.5

0.5

0.4

0.4

DNFB conc. (g %)

0.5

0.2

0.5

0.5

DNFB volume (mL)

0.3

0.2

1.0

0.8

Heating temperature (°C)

R.T.

40

60

40

Heating time (min)

30

20

25

40

5M HCl volume (mL)

0.1

0.1

0.2

0.1

λmax (nm)

338

339

357

352

-1

Standard conc. (mg mL )
Volume of standard solution (mL)
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Figure 3. Effect of buffer pH on the substit ution reaction of
amlodipine besylate (10.09 μg mL -1) and heptaminol hydrochloride
(7.61 μg mL -1) with 2,4-dinitrofluorobenzene.

Figure 5. Effect of borate buffer volume on the substitution reaction
of amlodipine besylate (9.64 μg mL -1) and heptaminol hydrochloride
(15.22 μg mL-1) with 2,4-dinitrofluorobenzene.
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Figure 4. Effect of borate buffer volume on the substitution reaction
of acetylcysteine (11.49 μg mL -1) and captopril (16.81 μg mL -1) with
2,4-dinitrofluorobenzene.

intensity for compound (II), whereas 0.3, 1 and 0.4 mL of
0.5% w/v reagent gave the maximum sensitivity for drugs
(I), (III) and (IV), respectively (Figures 6 and 7).
In order to obtain the highest and most stable absorbances, the effect of the reaction time and heating temperature was investigated (Figures 8-11). The optimal values
are presented in Table 1. For compound (I), the reaction
proceeds at room temperature and attains the maximum
sensitivity after 30 min. Moreover, heating resulted in lack
of reproducible results. For compound (II), heating at 40°C
for 20 min led to the maximum color formation. Compound
(III) required heating at 60°C for 25 min , while (IV) needed
heating at 40°C for 40 min to give full color intensity. The
reaction products were stable for at least 30 min.
II. Validation of the Method
The proposed method was validated according to the
USP 27(38) criteria.
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Volume (mL)

Figure 6. Effect of 2,4 -dinit rof lu roben zene (0.5% and 0.2%
respectively) volume on its substitution reaction with acetylcysteine
(10.9 μg mL -1) and captopril (12.68 μg mL -1).
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Figure 7. Effect of 2,4-dinitrof lurobenzene (0.5%) volume on its
substitution reaction with amlodipine besylate (10.48 μg mL -1) and
heptaminol hydrochloride (9.79 μg mL-1).
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Figure 8. Effect of reaction time at room temperat ure on the
substitution reaction of acetylcysteine (9.79 μg mL-1) with 2,4-dinitro
fluorobenzene.
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Figure 10. Effect of heating temperature and time on the substitution
reaction of amlodipine besylate (17.69 μg mL -1) with 2,4-dinitrofluor
obenzene.
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Figure 9. Effect of heating temperature and time on the substitution
reaction of captopril (13.5 μg mL -1) with 2,4-dinitrofluorobenzene.
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(I) Linearity
Linear correlations were found between the absorbance values and the concentration of the drugs over the
ranges stated in Table 2. The good linearity of the calibration graphs is evidenced by low variances around the
slopes and high correlation coefficients (Table 2).
(II) Accuracy
The accuracy was checked by calculating the recovery of the drugs spiked to the pharmaceutical preparations where good results were obtained (Table 2).
(III) Precision
In order to evaluate the precision of the proposed
method, solutions containing three different concentrations of each drug were prepared and analyzed in three
replicates. The mean relative standard deviations are
presented in Table 2.

Figure 11. Effect of heating temperature and time on the substitution
reaction of heptaminol hydrochloride(9.79 μg mL-1) with 2,4-dinitrofl
uorobenzene.

(IV) Limit of Detection and Limit of Quantitation
The detection and quantitation limits were calculated
from the standard deviation of the absorbance measurements obtained from a series of blank solutions for each
drug and are presented in Table 2.
III. Analytical Applications
The proposed method was successfully applied
to determine the selected drugs in their pharmaceutical preparations. The results obtained were statistically
compared to those of official or reported methods (32,39,40)
by the student’s t-test for accuracy and the variance ratio
F-test for precision as recorded in Table 3. The experimental values of t and F did not exceed the theoretical
values, indicating lack of significant difference between
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Table 2. Validation data for the determination of acetylcysteine (I), captopril (II), amlodipine besylate (III) and heptaminol hydrochloride
(IV) by the proposed method
Drug
Item

I

II

III

IV

λmax (nm)

338

339

357

352

Concentration range (µg mL-1)

4-12

2.4-16.8

8-28

5-25

Intercept (a)

-3.5 × 10-2

1.8 × 10-3

3.6 × 10-2

1.7 × 10-2

Variance of intercept (Sa2)

7.5 × 10-5

3.7 × 10-5

2.5 × 10-5

7.1 × 10-5

-2

-2

-2

Regression equationa

Slope (b)

7.0 × 10

4.8 × 10

3.3 × 10

3.5 × 10-2

Variance around slope (Sb2)

1.0 × 10-6

3.0 × 10-7

6.8 × 10-8

2.0 × 10-7

Correlation coefficient (r)

0.9996

0.9998

0.9999

0.9997

4.1 × 10-5

4.0 × 10-5

1.9 × 10-5

5.1 × 10-5

100.70 ± 1.25

99.61 ± 0.92

100.73 ± 1.05

99.83 ± 1.07

Precision (RSD%)

1.48

1.20

2.02

1.81

Limit of detection (µg mL-1)

0.97

0.38

0.58

1.45

3.24

1.27

1.93

4.85

Variance (S2y.x)
Accuracy (mean ± SD)

-1

Limit of quantitation (µg mL )
a

-1

A = a + bC, where C is the concentration in µg mL and A is absorbance unit.

Table 3. Assay results of drugs (I), (II), (III) and (IV) in their pharmaceutical preparations using the proposed method
Preparation

Supplier

Labeled amount

Recovery % ± SDa

Reference method(32,39,40)

Acetylcistein instant effervescent powder

South Egypt Drug

200 mg/sachet

101.94 ± 1.11

102.85 ± 0.64

Industries Co.

t = 1.59
F = 3.00

CapotenTM tablets

Bristol Myers
Squibb, Egypt

25 or 50 mg captopril/tab

100.50 ± 1.45

101.99 ± 0.54

t = 2.15
F = 6.24

Capozide tablets

Bristol Myers
Squibb, Egypt

25 mg captopril
and 12.5 mg
hydrochlorothiazide/tab

100.90 ± 1.62

Norvasc tablets

Pfizer, Egypt

The equivalent
of 5 mg
amlodipine/tab

99.28 ± 0.46

100.0 ± 0.65

t = 2.02
F = 2.01

Lotrel tablets*

Novartis, USA

The equivalent of
5 mg amlodipine and
10 or 20 mg
benazepril/tab

100.87 ± 0.76

Corasor tablets

Amoun Pharmaceutical
Co., Egypt

150 mg heptaminol
hydrochloride/tab

101.15 ± 1.33

101.67 ± 1.84

t = 0.51
F = 1.92

Respirin drops

Pharco
Pharmaceuticals, Egypt

150 mg heptaminol
hydrochloride/mL

99.37 ± 0.83
t = 2.06
F = 1.39

a

Each value is the mean of five measurements.
b
Theoretical values for t- and F- at p = 0.05 are 2.31 and 6.39, respectively.
32
Hantzch condensation reaction method for heptaminol.
39
The BP- HPLC- method of captopril for both acetylcysteine and captopril.
40
Reversed-phase HPLC method for amlodipine.
*Laboratory prepared tablets as documented in the Physician Desk Reference (PDR).

98.36 ± 0.71
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the compared methods. Based on the data in Table 3, it
was found that amino compounds demonstrated better
results in the proposed method compared to those of
the reference methods concerning the values of the SD.
However, the thiols demonstrated relatively less satisfactory results. This may be attributed to the greater
nucleophilicity of the amino compounds than the thiols;
therefore, reaction in the former case goes more smoothly
resulting in better reproducibility and hence better values
of standard deviations. Furthermore, applicability of
the developed method to multi-component pharmaceutical formulations has been verified by analyzing captopril
in the presence of hydrochlorothiazide and amlodipine
in combination with benazepril where no interference
was made by these common co-formulated drugs as
evidenced by the good recoveries obtained. The results
are shown in Table 3.

CONCLUSIONS
The proposed method can be recommended for
routine quantitative determination of the studied drugs
in quality control laboratories where modern equipments
are unavailable. The absence of interference from added
excipients, additives and some co-formulated drugs is
a noted advantage. Another advantage was simplicity of the method as evidenced by direct application of
the reaction to the amine salts like amlodipine besylate
and heptaminol hydrochloride without the need of prior
conversion to the base and subsequent extraction.
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